Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Non-Current Debt (2020 - 2025)

Historic Non-Current Debt for Vivos Therapeutics (VVOS) over the last 3 years, with Q3 2025 value amounting to $8.4 million.

  • Vivos Therapeutics' Non-Current Debt changed N/A to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year change of. This contributed to the annual value of $423000.0 for FY2020, which is N/A changed from last year.
  • Per Vivos Therapeutics' latest filing, its Non-Current Debt stood at $8.4 million for Q3 2025.
  • Over the past 5 years, Vivos Therapeutics' Non-Current Debt peaked at $8.4 million during Q3 2025, and registered a low of $105906.0 during Q1 2021.